Focus Partners Advisor Solutions LLC Boosts Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY

Focus Partners Advisor Solutions LLC increased its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 533.0% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 5,127 shares of the biopharmaceutical company’s stock after buying an additional 4,317 shares during the quarter. Focus Partners Advisor Solutions LLC’s holdings in Alnylam Pharmaceuticals were worth $2,282,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Root Financial Partners LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter worth $25,000. Salomon & Ludwin LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the third quarter valued at about $27,000. Atlantic Union Bankshares Corp purchased a new stake in shares of Alnylam Pharmaceuticals in the second quarter valued at about $30,000. ORG Partners LLC increased its position in Alnylam Pharmaceuticals by 70.2% during the third quarter. ORG Partners LLC now owns 80 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 33 shares during the last quarter. Finally, Aster Capital Management DIFC Ltd purchased a new position in Alnylam Pharmaceuticals during the third quarter worth about $36,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals News Roundup

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Neutral Sentiment: Short-interest reads are unreliable — filings report a “large increase” but show 0 shares and NaN changes, with days-to-cover of 0.0; this appears to be a data error and is unlikely to be driving meaningful buying or selling pressure.
• Neutral Sentiment: Protego Biopharma appointed John M. Maraganore, Ph.D., to its board. Maraganore is a former Alnylam CEO; the move is an external board appointment and is unlikely to materially affect Alnylam’s fundamentals. Protego Biopharma Appoints John M. Maraganore
• Negative Sentiment: Insider sales by senior management: multiple executives sold shares in early March — CEO Yvonne Greenstreet sold 6,799 shares (~$2.23M) reducing her holding by 6.45%; several EVPs (Tolga Tanguler, Kevin J. Fitzgerald, Pushkal Garg, Jeffrey V. Poulton) also sold blocks (each mid-five-figure shares, roughly $0.5M–$0.72M per filing), trimming their positions by ~3–7%. These clustered insider sales can be perceived negatively by the market even if they are routine diversification. SEC filings: Greenstreet SEC filing Tanguler SEC filing Fitzgerald SEC filing Garg SEC filing Poulton SEC filing

Alnylam Pharmaceuticals Trading Up 2.7%

Shares of NASDAQ ALNY opened at $327.30 on Thursday. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $495.55. The company has a current ratio of 2.76, a quick ratio of 2.71 and a debt-to-equity ratio of 1.28. The stock has a fifty day simple moving average of $355.63 and a 200-day simple moving average of $416.41. The stock has a market capitalization of $43.41 billion, a PE ratio of 191.40 and a beta of 0.36.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.43 by ($0.18). Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The firm had revenue of $1.10 billion for the quarter, compared to analyst estimates of $1.16 billion. During the same period in the previous year, the company posted ($0.65) EPS. Alnylam Pharmaceuticals’s revenue was up 84.9% on a year-over-year basis. On average, equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Tolga Tanguler sold 1,598 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $327.65, for a total value of $523,584.70. Following the completion of the transaction, the executive vice president owned 36,606 shares of the company’s stock, valued at $11,993,955.90. This trade represents a 4.18% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Kevin Joseph Fitzgerald sold 1,652 shares of the company’s stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $319.73, for a total value of $528,193.96. Following the sale, the executive vice president directly owned 21,860 shares in the company, valued at $6,989,297.80. This represents a 7.03% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 53,923 shares of company stock valued at $18,072,087. Corporate insiders own 1.50% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Truist Financial dropped their price target on shares of Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating for the company in a research note on Thursday, January 8th. Oppenheimer initiated coverage on Alnylam Pharmaceuticals in a research report on Wednesday, January 7th. They issued an “outperform” rating and a $500.00 price objective for the company. Wall Street Zen cut Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 14th. Weiss Ratings raised Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Thursday, January 15th. Finally, Chardan Capital cut their price objective on Alnylam Pharmaceuticals from $475.00 to $425.00 and set a “buy” rating for the company in a research report on Friday, February 13th. One analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $477.96.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.